HomeREGULATORY
REGULATORY

Patient Dies due to Mix-Up of Lixiana, Rifxima; PMDA, Companies Issue Warning Statement
(Oct.26.2017)

The Pharmaceuticals and Medical Devices Agency (PMDA) issued a warning statement on its website on October 25 regarding the death of a patient who received Daiichi Sankyo’s oral anticoagulant Lixiana (edoxaban) instead of ASKA Pharmaceutical’s oral antibiotic Rifxima (rifaximin) due to a dispensing error caused by a brand name confusion ...
(LOG IN FOR FULL STORY)

News Calendar